Repligen (RGEN) announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Johnson will lead the investor relations team’s engagement with the investment community, reporting to the company’s CFO, Jason Garland. Most recently, Johnson served as Managing Director, Research Analyst at Stephens, where he followed the life sciences tools and pharma services sector.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Promising Outlook for Repligen: Strong Order Momentum, Strategic Positioning, and Growth Opportunities
- Repligen initiated with an In Line at Evercore ISI
- Repligen’s Strategic Acquisition of 908 Devices’ Assets: A Buy Rating for Long-term Shareholder Value
- Repligen’s Strategic Acquisition: Hold Rating Amid Short-term Financial Dilution and Long-term Growth Potential
- Repligen deal can expand bioprocessing opportunities, says RBC Capital